By inhibiting sodium and glucose reabsorption from the proximal tubules, sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce cardiovascular mortality in patients with and without diabetes mellitus. Here, SLC5A2 is linked to diabetes mellitus.